Figure 5.
Sensitivity of mAbs D2, F9 and C1-13 against rPfHRP2. The binding efficacy of mAbs against serially diluted recombinant PfHRP2 is determined by ELISA (Left panel) and dot blot (Right panel). A: 5 μg/mL of mAbs; B: 1 μg/mL of mAbs. Dot line represents cut-off OD absorbance at 1.0.